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Abstract
Background: Cost and quality-adjusted life-years (QALYs) gained by quadrivalent influenza vaccine (QIV) versus
trivalent influenza vaccine (TIV) in Hong Kong elderly were estimated over 9 seasons.
Methods: TIV-unmatched influenza B infection rates with QIV versus TIV were estimated by an epidemiology
model. Model parameters included percentages of influenza B lineages in circulation, influenza B-associated hospital
admission, age-specific population, vaccine coverage and effectiveness. Incremental cost per QALY gained (ICER) by
QIV versus TIV were estimated from Hong Kong’s societal perspective.
Results: Mean reduction in influenza B infection rate was 191.3 (95%CI 45.1-337.5) per 100,000 population aged ≥65 years.
Highest cost savings and QALYs gained by QIV occurred in 2007 with high percentage of TIV-unmatched strain (92.9%) for
age groups 65–79 years (USD266,473 and 22.8 QALYs) and ≥80 years (USD483,461 and 27.3 QALYs). ICERs of QIV were
below willingness-to-pay for age group 65–79 years in 6, 5 and 3 years when QIV cost + USD1 +USD2 and + USD5
more than TIV, respectively. For age group ≥80 years, ICERs of QIV were below willingness-to-pay in 7 and 5 years when
QIV cost + USD1 and + USD5, correspondingly.
Conclusions: Acceptance of QIV to be cost-effective in Hong Kong elderly was subject to QIV unit cost and percentage of
circulating TIV-unmatched influenza B lineages.
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Background
We recently reported the percentages of influenza B
lineages (B/Victoria and B/Yamagata) in clinical isolates
in 2000–2010 and found that co-circulation of both
influenza B lineages was very common in Hong Kong
[1]. Furthermore, one of the influenza B lineages predomi-
nated (accounting for over 80% of the circulating influ-
enza B strains) in six of the ten years. These predominated
years were associated with increased risk of hospitalization
by 1.4-fold. The seasonal trivalent influenza vaccine (TIV)
covers two subtypes of influenza A (A/H1N1 and A/H3N2)
plus one of the two influenza B lineages circulating in
humans, and TIV only matched the predominated
influenza B strain in two of these six predominated
years.
Findings in literature suggested that including two line-
ages of influenza B in a quadrivalent influenza vaccine
(QIV) would have a positive impact in terms of cost saving
and reducing hospitalization related to influenza infection
[2,3]. To further quantify the clinical and economic impact
of QIV, we estimated the difference in costs and quality-
adjusted life-years (QALYs) gained by QIV, when compared
to TIV, in elderly population over the period of 2001–2010
from a societal perspective of Hong Kong.
Methods
In the present analysis, we estimated the potential cost
and QALYs difference of influenza B, when compared
to TIV, from 2001–2010 years in elderly population
(aged ≥65 years) in Hong Kong. Year 2009 was excluded
as it was dominated by the novel pandemic influenza A
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2009 H1N1. Events caused by infection of the TIV-
unmatched influenza B lineage in each year were calculated
by an epidemiology model. The infections caused by the
influenza B lineage or influenza A subtypes covered by both
TIV and QIV were excluded, assuming that there were no
change in the infection rates. The costs and QALYs loss for
symptomatic patients who received medical care in out-
patient and hospital setting were estimated from the event
rates. The parameters used for estimation of clinical events,
cost difference and QALYs gained by QIV versus TIV were
listed in Table 1. All model parameters were obtained from
published literature.
Clinical events analysis
For each year, the hospitalization rate of target B lineage
was calculated using the influenza B hospital admission rate
and the percentage of target influenza B lineage identified
in the isolates reported in our previous cohort study [1].
Briefly, in this prior study we identified hospitalized patients
with laboratory confirmed influenza virus A or B infection
Table 1 Parameters for calculation of event rates, costs and QALYs with QIV versus TIV
Parameter Values References
Clinical inputs
Influenza vaccine coverage (≥65 years) 39.1% 15
TIV vaccine effectiveness against influenza B (2001–2010) 0.45-0.75 7-14
Reduction in TIV influenza B vaccine effectiveness against TIV-unmatched influenza B lineage 30% 6
Influenza B hospitalization rate (2001–2010) by age group (per 100,000): 1
65-79 years 1-40.8
≥80 years 0-222.1
Hong Kong population (2001–2010) by age group: 24
65-79 years 600,986-665,642
≥80 years 146,066-257,966
Influenza B lineage in circulation (2001–2010) 1
Yamagata 5.3%-96.3%
Victoria 3.7-94.7%
Case-fatality ratio 0.05% 5
Percent of inpatient cases with ICU admission: 2.4% 4
Mortality rate of influenza B in ≥65 years inpatient cases 5.9% 1
Utility
Utility score for >65 years 0.84 25
Utility loss 16-22
Outpatient care 0.40
Hospitalization without ICU care 0.50
Hospitalization with ICU care 0.62
Life expectancy in Hong Kong (years) 83 24
Cost (USD)*
Cost of outpatient clinic (per visit) 49 26
Number of clinic visit for patients without hospitalization 1 Assumption
Cost of hospitalization without ICU care (per day) 600 26
Cost of hospitalization with ICU care (per day) 2,949 26
Length of illness (days)
Outpatient care 7 23
Hospitalization (length of stay) 10.8 4
Caregiver salary per day 47 24
Labor force rate 68% 24
Unemployment rate 3.7% 24
*1 USD =7.8 HKD.
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and the circulation pattern of influenza B lineage in the
Prince of Wales Hospital (a 1300-bed Hong Kong teaching
hospital), and calculated age-stratified population-based
hospitalization rates of influenza A and B for years from
2000–2010 (excluding 2009 for the same reason above).
The intensive care unit (ICU) admission rate was cal-
culated by hospitalization rate of target lineage together
with ICU admission rate among hospitalized patients
[4]. The mortality rate of influenza B among hospitalized
patients was retrieved from patients aged ≥65 years in the
same cohort of our previous study [1]. The expected
annual infection rate of target lineage was estimated
using the mortality rate and a case-fatality ratio of
influenza [5]. The rate of outpatient care was further calcu-
lated as the difference of estimated annual infection rate
and hospitalization rate. To estimate the reduction in event
rates of outpatient care, hospitalization, ICU admission and
death with the use of QIV versus TIV, the epidemiology
model described by Reed et al. was adoped [2]:
(1)Expected event rate without influenza vaccination =
Event rate with TIV/(1 − (VC × VETIV))
(2)Expected event rate with QIV = expected event rate
without influenza vaccination × (1− (VC × VEQIV))
where VC and VE were the vaccine coverage and
vaccine effectiveness against the TIV-unmatched
lineage, respectively.
(3)Reduction in event rate = Event rate with TIV −
expected event rate with QIV.
The VETIV against the TIV-unmatched influenza B
lineage was estimated to be reduced by 30% [6]. The
VEQIV against the TIV-unmatched influenza B lineage
was assumed to be the same as VE of TIV against the
TIV-selected influenza B lineage, and the year-specific
VE was retrieved from literature reported in the period
of 2001–2010 [7-14]. The year 2012 age-specific influ-
enza vaccine coverage rate (39.1%) in elderly published
by the Department of Health of Hong Kong was applied
in the present analysis for 9 seasons [15].
The reduction in case numbers of each event (out-
patient care, hospitalization, ICU admission and death)
were then calculated by multiplying the change in event
rate and the population of ≥65 years for each year.
QALY analysis
The QALYs gained by QIV were calculated using the
number of reduced infected cases, and the utility value
and duration of time-spent in each of the four statuses:
(1) Outpatient care, (2) hospitalization without ICU
admission, (3) ICU care, and (4) death. The utilities were
retrieved from health-related quality of life reported from
literature (Table 1) [16-22]. The time-spent in outpatient
care and hospitalization were the length of outpatient
duration of illness [23] and length of hospital stay [4], cor-
respondingly. The QALYs loss of death was estimated using
life expectancy in Hong Kong and age-specific utility value
for ≥65 years [24,25]. The QALYs loss in both vaccine arms
was discounted to 2014 with 3% annual discounted rate.
Cost analysis
Both direct medical cost and indirect cost of reduced
cases of the TIV-unmatched influenza B lineage were con-
sidered as cost savings of QIV, from the societal perspec-
tive of Hong Kong. Direct medical cost included costs of
outpatient care and hospitalization. The cost per out-
patient clinic visit and cost per hospital day (with and
without ICU care) were estimated from the 2014 charges
of the Hospital Authority (HA). HA is the largest, non-
profit-making public health organization in Hong Kong.
Assuming the charges listed by the Hospital Authority rep-
resent only the cost components (including labor costs)
with no addition of profits, the cost per general out-
patient visit and daily cost of hospitalization were therefore
approximated using the Hospital Authority charges [26].
Productivity loss of caregivers of elderly patients was
estimated by the median daily income (non-gender spe-
cific) of the population in Hong Kong [24], and duration
of hospitalization for inpatient care. For patients receiv-
ing only outpatient care, the duration of productivity
loss was limited to days attending outpatient clinic. The
number of clinic visit was assumed to be one time for a
conservative estimation on both direct and indirect costs
of outpatient care. The proportion of employed care-
givers was estimated by the percentage of Hong Kong
population in the labor force and the employment rate
among the labor force [24].
Cost-effectiveness analysis
The incremental cost per QALY gained (ICER) by QIV
versus TIV was calculated using the following equation:
(Additional vaccine cost of QIV versus TIV – Cost-
savings of QIV)/QALYs gained by reduced events,
where additional vaccine cost of QIV was calculated by:
Additional unit cost of QIV versus TIV × age-specific
coverage rate × population of age group
The current unit cost of TIV in Hong Kong is USD7.7.
Four levels of additional cost (the unit cost of QIV to be
USD1, 2, 5 and 10 more than TIV) were considered in the
cost-effectiveness analysis. As recommended by the World
Health Organization (WHO), three-fold of gross domestic
product (GDP) per capita was used as the threshold of
willingness-to-pay per QALY [27]. A scenario with ICER
of QIV less than 3-fold of GDP per capita of Hong Kong
was considered as cost-effective.
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Results
The reduction in expected events rates of TIV-unmatched
influenza B by QIV versus TIV are shown in Table 2. The
mean reduction in influenza infection rate for elderly
aged ≥65 years was 191.3 (95%CI 45.1-337.5) per
100,000 in 2001–2010. Age-specific reduction in the
age group 65–79 years was 104.8 (95%CI 27.2-182.4)
per 100,000, and 451.4 (95%CI 87.7-815.1) per 100,000
in population aged ≥80 years.
The highest total cost savings and QALYs gained by
QIV in age group 65–79 years occurred in year 2007
(USD266,473 and 22.8 QALYs), followed by year 2004
(USD256,127 and 21.9 QALYs), and year 2008 (USD191,105
and 16.4 QALYs) (Table 3). Similarly, QIV had the highest
cost-saving and QALYs gained from reduced cases of influ-
enza B in age group ≥80 years in 2007 (USD483,461 and
27.3 QALYs), year 2008 (USD344,103 and 19.5 QALYs) and
year 2004 (USD218,829 and 12.4 QALYs). In the year
2002, no influenza B virus was identified in hospital
admissions at the Prince of Wales Hospital for age groups
65–79 years and ≥80 years. The expected reductions in
infection, cost-saving and additional QALYs gained by
QIV were considered to be zero in 2002.
The GDP per capita of Hong Kong was USD36,557.32
Using 3-time GDP per capita (USD109,671) as the
threshold of willingness-to-pay, ICERs of QIV indicated
that it was more cost-effective than TIV for age group
65–79 years in 6 years when QIV cost USD1 more than
TIV (Table 4). When QIV was more costly than TIV by
USD2, USD5 and USD10, it was more cost-effective
than TIV in 5, 3 and 2 years, respectively. In the age
group ≥80 years, the ICERs of QIV was below the
threshold of willingness-to-pay in 7 years when QIV
versus TIV cost level was + USD1. QIV remained to be
cost-effective in 5 years when it cost up to USD5 more
than TIV. It was cost-effective in 3 years when it cost
USD10 more than TIV.
Discussion
The present analysis quantified the expected reduction
in TIV-unmatched influenza B infection rate, direct
medical cost and indirect cost of productivity loss, and
QALYs loss if QIV was available in Hong Kong during
2001–2010. The symptomatic infection rates were re-
duced by 191.3 (95%CI 45.1-337.5) per 100,000 elderly
Table 2 Reduction in expected event rates of
TIV-unmatched influenza B by QIV versus TIV in Hong
Kong elderly
Year Rate reduction (per 100,000)
Symptomatic influenza Outpatient Hospitalization Dead
Age 65–79 years
2001 2.6809 2.6582 0.0227 0.0013
2002* 0.0000 0.0000 0.0000 0.0000
2003 3.7933 3.7611 0.0321 0.0019
2004 282.0652 279.6748 2.3904 0.1410
2005 84.4697 83.7538 0.7158 0.0422
2006 27.5809 27.3472 0.2337 0.0138
2007 282.9799 280.5818 2.3981 0.1415
2008 201.6311 199.9223 1.7087 0.1008
2010 58.1889 57.6958 0.4931 0.0291
Age ≥80 years
2001 1.9449 1.9285 0.0165 0.0010
2002* 0.0000 0.0000 0.0000 0.0000
2003 42.1055 41.7487 0.3568 0.0211
2004 838.6402 831.5331 7.1071 0.4193
2005 204.2730 202.5419 1.7311 0.1021
2006 49.7802 49.3583 0.4219 0.0249
2007 1540.4373 1527.3828 13.0546 0.7702
2008 1032.5602 1023.8097 8.7505 0.5163
2010 352.9492 349.9581 2.9911 0.1765
*In 2002, no influenza B virus was identified from patients admitted to the
Prince of Wale Hospital for age groups 65–79 years and ≥80 years. The
expected reductions in event rates were considered as zero.
Table 3 QALY gained and cost savings of QIV versus TIV
Year QALYs Direct cost Indirect cost Total cost
Age 65–79 years
2001 0.199 1,781 543 2,324
2002* 0 0 0 0
2003 0.291 2,600 792 3,392
2004 21.940 196,311 59,816 256,127
2005 6.670 59,679 18,184 77,863
2006 2.210 19,777 6,026 25,803
2007 22.826 204,241 62,232 266,473
2008 16.370 146,474 44,631 191,105
2010 4.785 42,818 13,047 55,864
Age ≥80 years
2001 0.023 314 96 410
2002* 0 0 0 0
2003 0.581 7,880 2,401 10,281
2004 12.372 167,723 51,105 218,829
2005 3.207 43,477 13,247 56,724
2006 0.829 11,234 3,423 14,657
2007 27.335 370,553 112,907 483,461
2008 19.455 263,741 80,362 344,103
2010 7.425 100,651 30,668 131,319
*In 2002, no influenza B virus was identified from patients admitted to the
Prince of Wale Hospital for age groups 65–79 years and ≥80 years. The
expected reductions in infected cases, cost-saving and additional QALYs
gained with QIV were considered as zero.
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aged ≥65 years in the 2001–2010, comparable to the es-
timated reduction in the US reported by Reed et al.
(ranged from 1–440 per 100,000 in 2001–2008) [2].
As demonstrated by the annual cost savings and
QALYs loss averted by QIV (Table 2), and QIV would be
more cost-effective than TIV if the unit cost of QIV is
the same as TIV (additional unit cost = USD0) in all
9 years (except year 2002). The number of years in
which QIV was more cost-effective than TIV decreased
in both age groups 65–79 years and ≥80 year when the
unit cost of QIV increased by USD1-10 (Table 3). Our
results were different from the findings of an economic
study of QIV in the US [3]. Lee et al. reported positive
cost savings (including both direct and indirect costs) by
QIV when the unit cost of QIV was USD5-30 more than
TIV, based upon infection rate reduction reported by
Reed et al. In the present analysis, QIV would cost more
to gain QALYs (as indicated by a positive value of ICER)
in most of the years when QIV cost more than TIV by
USD1-10. The difference was mainly caused by lower
healthcare costs in Hong Kong comparing to the US for
inpatient (USD1,800-6,600 versus USD4,221-11,372) and
outpatient care (USD49 versus USD76-102). For every
case of infection averted, less direct cost of treatment
was saved in Hong Kong versus US because of the lower
cost of care.
In the present study, QIV was cost-effective in year
2007 at four cost levels (+USD1, +USD2, +USD5 and +
USD10). The cost savings and QALYs gained by QIV
were the highest in this year. It could be explained by
the fact that a high percentage of circulating influenza B
lineages in Hong Kong were not covered by TIV (92.9%)
and the hospitalization rate for influenza B in the elderly
was the highest in 2007 [1]. The cost-effectiveness of the
influenza vaccine tends to be enhanced when the ex-
pected hospitalization rate without the vaccine is high
[28]. The expected QALYs gained and cost savings of
QIV were sufficient to overcome the economic impact
of additional cost of QIV and it therefore remained cost-
effective over a broad range of additional vaccine cost.
Our study was limited by using a single source (one
teaching hospital) of influenza B hospital admission rates
and circulating virus lineages for the calculation of
population-based influenza B infection rate in Hong
Kong elderly. The infection rate was estimated by the
case-fatality ratio, yet this information was not available
from Hong Kong. A case-fatality ratio derived from US
was used, as the estimated influenza-related mortality
rates were generally similar in Hong Kong and the US
[29,30]. We assumed that patients in the outpatient set-
ting would seek care at medical clinic for one time, as
Chinese older people in Hong Kong tend to perceive in-
fluenza as a serious illness [31]. Some patients would
use home remedies or over-the-counter preparation to
Table 4 ICER# of QIV versus TIV
Year ICER
Age (years) 65-79 ≥80








































# ICER = incremental cost per QALY saved by QIV. Using the threshold of
3-time gross domestic product per capita in Hong Kong as the willingness-to-pay
per QALY, QIV was cost-effective with ICER USD109,671 or less (bold). A negative
value of ICER indicated that QIV was less costly than TIV and gained higher QALYs.
*NE = Not effective. ICER was not calculated in 2002 because the expected
reduction in infection and expected QALY gained were zero.
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alleviate influenza symptoms, and the cost-saving of QIV
might be overestimated. On the other hand, the QALYs
loss of caregivers was not included in the analysis and the
QALY saved by QIV might therefore be underestimated.
The current cost and QALYs were calculated based upon
the vaccine coverage of 39.1% and herd immunity effect
was not included in the analysis. The study findings are
likely to change if the vaccine coverage is improved in eld-
erly (and therefore generates herd immunity), probably
showing more prominent saving in cost and QALYs with
QIV comparing to TIV. Sensitivity analysis was not con-
ducted in the present study. Expected cost and clinical out-
comes were calculated for 9 seasons using year-specific key
parameters. The change of cost and clinical outcomes was
found to be sensitive to the variation of key year-specific
parameters (namely the percentage of circulating TIV-
unmatched influenza B lineage and hospitalization rate).
Using year-specific inputs has therefore served the purpose
of sensitivity analysis.
Conclusions
In conclusion, QIV could reduce direct and indirect costs
of influenza B infection and gain higher QALYs when
compared to TIV in the elderly population of Hong Kong.
The acceptance of QIV to be cost-effective in Hong Kong
elderly was highly subject to the unit cost of QIV versus
TIV and the percentage of circulating TIV-unmatched in-
fluenza B lineages.
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